السوق العالمية لعلاج مرض الطعم ضد المضيف (GvHD) – اتجاهات الصناعة والتوقعات حتى عام 2031

TABLE 1 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 2 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 3 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 4 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 5 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 6 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 7 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 8 GLOBAL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 9 GLOBAL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 10 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 11 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 12 GLOBAL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 13 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 14 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 15 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 16 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 17 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 18 GLOBAL ORAL IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 19 GLOBAL INTRAVENOUS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 20 GLOBAL TOPICAL IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 21 GLOBAL OTHERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 22 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 23 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 24 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 25 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 26 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 27 GLOBAL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 28 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 29 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 30 GLOBAL THERAPY IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 31 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 32 GLOBAL ADULTS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 33 GLOBAL PEDIATRIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 34 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 35 GLOBAL FEMALE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 36 GLOBAL MALE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 37 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 38 LOBAL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 39 GLOBAL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 40 GLOBAL TRANSPLANT CENTERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 41 GLOBAL INSTITUTES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 42 GLOBAL SPECIALITY CENTERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 43 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 44 GLOBAL DIRECT TENDER IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 45 GLOBAL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 46 GLOBAL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 47 GLOBAL OTHERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 48 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 49 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 50 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 51 NORTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 52 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 53 NORTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 54 NORTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 55 NORTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 56 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 57 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 58 NORTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 59 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 60 NORTH AMERICA IMMUNOSUPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 61 NORTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 62 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 63 NORTH AMERICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 64 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 65 NORTH AMERICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 66 NORTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 67 NORTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 68 NORTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 69 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 70 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 71 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 72 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 73 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 74 NORTH AMERICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 75 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 76 NORTH AMERICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 77 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 78 U.S. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 79 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 80 U.S. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 81 U.S. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 82 U.S. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 83 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 84 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 85 U.S. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 86 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 87 U.S. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 88 U.S. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 89 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 90 U.S. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 91 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 92 U.S. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 93 U.S. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 94 U.S. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 95 U.S. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 96 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 97 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 98 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 99 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 100 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 101 U.S. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 102 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 103 U.S. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 104 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 105 CANADA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 106 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 107 CANADA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 108 CANADA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 109 CANADA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 110 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 111 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 112 CANADA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 113 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 114 CANADA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 115 CANADA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 116 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 117 CANADA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 118 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 119 CANADA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 120 CANADA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 121 CANADA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 122 CANADA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 123 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 124 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 125 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 126 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 127 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 128 CANADA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 129 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 130 CANADA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 131 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 132 MEXICO MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 133 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 134 MEXICO IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 135 MEXICO CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 136 MEXICO MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 137 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 138 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 139 MEXICO CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 140 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 141 MEXICO IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 142 MEXICO CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 143 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 144 MEXICO ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 145 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 146 MEXICO IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 147 MEXICO CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 148 MEXICO PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 149 MEXICO PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 150 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 151 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 152 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 153 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 154 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 155 MEXICO HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 156 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 157 MEXICO RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 158 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 159 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 160 EUROPE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 161 EUROPE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 162 EUROPE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 163 EUROPE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 164 EUROPE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 165 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 166 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 167 EUROPE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 168 EUROPE CORTICOSTEROIDS GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 169 EUROPE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 170 EUROPE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 171 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 172 EUROPE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 173 EUROPE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 174 EUROPE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 175 EUROPE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 176 EUROPE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 177 EUROPE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 178 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 179 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 180 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 181 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 182 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 183 EUROPE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 184 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 185 EUROPE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 186 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 187 GERMANY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 188 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 189 GERMANY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 190 GERMANY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 191 GERMANY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 192 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 193 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 194 GERMANY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 195 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 196 GERMANY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 197 GERMANY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 198 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 199 GERMANY ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 200 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 201 GERMANY IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 202 GERMANY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 203 GERMANY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 204 GERMANY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 205 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 206 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 207 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 208 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 209 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 210 GERMANY HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 211 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 212 GERMANY RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 213 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 214 FRANCE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 215 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 216 FRANCE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 217 FRANCE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 218 FRANCE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 219 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 220 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 221 FRANCE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 222 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 223 FRANCE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 224 FRANCE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 225 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 226 FRANCE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 227 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 228 FRANCE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 229 FRANCE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 230 FRANCE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 231 FRANCE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 232 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 233 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 234 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 235 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 236 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 237 FRANCE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 238 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 239 FRANCE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 240 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 241 ITALY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 242 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 243 ITALY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 244 ITALY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 245 ITALY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 246 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 247 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 248 ITALY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 249 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 250 ITALY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 251 ITALY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 252 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 253 ITALY ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 254 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 255 ITALY IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 256 ITALY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 257 ITALY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 258 ITALY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 259 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 260 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 261 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 262 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 263 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 264 ITALY HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 265 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 266 ITALY RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 267 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 268 U.K. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 269 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 270 U.K. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 271 U.K. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 272 U.K. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 273 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 274 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 275 U.K. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 276 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 277 U.K. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 278 U.K. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 279 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 280 U.K. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 281 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 282 U.K. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 283 U.K. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 284 U.K. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 285 U.K. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 286 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 287 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 288 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 289 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 290 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 291 U.K. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 292 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 293 U.K. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 294 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 295 SPAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 296 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 297 SPAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 298 SPAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 299 SPAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 300 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 301 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 302 SPAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 303 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 304 SPAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 305 SPAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 306 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 307 SPAIN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 308 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 309 SPAIN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 310 SPAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 311 SPAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 312 SPAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 313 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 314 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 315 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 316 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 317 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 318 SPAIN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 319 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 320 SPAIN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 321 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 322 BELGIUM MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 323 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 324 BELGIUM IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 325 BELGIUM CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 326 BELGIUM MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 327 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 328 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 329 BELGIUM CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 330 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 331 BELGIUM IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 332 BELGIUM CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 333 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 334 BELGIUM ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 335 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 336 BELGIUM IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 337 BELGIUM CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 338 BELGIUM PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 339 BELGIUM PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 340 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 341 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 342 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 343 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 344 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 345 BELGIUM HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 346 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 347 BELGIUM RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 348 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 349 RUSSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 350 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 351 RUSSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 352 RUSSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 353 RUSSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 354 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 355 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 356 RUSSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 357 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 358 RUSSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 359 RUSSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 360 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 361 RUSSIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 362 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 363 RUSSIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 364 RUSSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 365 RUSSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 366 RUSSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 367 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 368 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 369 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 370 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 371 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 372 RUSSIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 373 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 374 RUSSIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 375 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 376 SWITZERLAND MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 377 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 378 SWITZERLAND IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 379 SWITZERLAND CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 380 SWITZERLAND MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 381 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 382 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 383 SWITZERLAND CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 384 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 385 SWITZERLAND IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 386 SWITZERLAND CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 387 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 388 SWITZERLAND ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 389 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 390 SWITZERLAND IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 391 SWITZERLAND CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 392 SWITZERLAND PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 393 SWITZERLAND PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 394 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 395 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 396 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 397 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 398 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 399 SWITZERLAND HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 400 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 401 SWITZERLAND RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 402 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 403 DENMARK MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 404 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 405 DENMARK IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 406 DENMARK CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 407 DENMARK MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 408 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 409 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 410 DENMARK CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 411 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 412 DENMARK IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 413 DENMARK CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 414 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 415 DENMARK ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 416 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 417 DENMARK IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 418 DENMARK CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 419 DENMARK PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 420 DENMARK PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 421 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 422 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 423 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 424 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 425 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 426 DENMARK HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 427 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 428 DENMARK RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 429 REST OF EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 430 ASIA-PACIFIC GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 431 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 432 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 433 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 434 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 435 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 436 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 437 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 438 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 439 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 440 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 441 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 442 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 443 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 444 ASIA-PACIFIC ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 445 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 446 ASIA-PACIFIC IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 447 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 448 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 449 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 450 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 451 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 452 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 453 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 454 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 455 ASIA-PACIFIC HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 456 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 457 ASIA-PACIFIC RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 458 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 459 JAPAN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 460 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 461 JAPAN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 462 JAPAN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 463 JAPAN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 464 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 465 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 466 JAPAN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 467 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 468 JAPAN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 469 JAPAN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 470 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 471 JAPAN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 472 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 473 JAPAN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 474 JAPAN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 475 JAPAN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 476 JAPAN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 477 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 478 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 479 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 480 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 481 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 482 JAPAN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 483 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 484 JAPAN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 485 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 486 CHINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 487 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 488 CHINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 489 CHINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 490 CHINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 491 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 492 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 493 CHINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 494 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 495 CHINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 496 CHINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 497 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 498 CHINA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 499 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 500 CHINA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 501 CHINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 502 CHINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 503 CHINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 504 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 505 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 506 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 507 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 508 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 509 CHINA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 510 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 511 CHINA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 512 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 513 AUSTRALIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 514 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 515 AUSTRALIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 516 AUSTRALIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 517 AUSTRALIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 518 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 519 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 520 AUSTRALIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 521 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 522 AUSTRALIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 523 AUSTRALIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 524 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 525 AUSTRALIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 526 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 527 AUSTRALIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 528 AUSTRALIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 529 AUSTRALIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 530 AUSTRALIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 531 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 532 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 533 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 534 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 535 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 536 AUSTRALIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 537 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 538 AUSTRALIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 539 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 540 SOUTH KOREA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 541 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 542 SOUTH KOREA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 543 SOUTH KOREA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 544 SOUTH KOREA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 545 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 546 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 547 SOUTH KOREA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 548 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 549 SOUTH KOREA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 550 SOUTH KOREA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 551 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 552 SOUTH KOREA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 553 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 554 SOUTH KOREA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 555 SOUTH KOREA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 556 SOUTH KOREA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 557 SOUTH KOREA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 558 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 559 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 560 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 561 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 562 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 563 SOUTH KOREA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 564 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 565 SOUTH KOREA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 566 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 567 INDIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 568 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 569 INDIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 570 INDIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 571 INDIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 572 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 573 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 574 INDIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 575 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 576 INDIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 577 INDIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 578 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 579 INDIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 580 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 581 INDIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 582 INDIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 583 INDIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 584 INDIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 585 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 586 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 587 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 588 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 589 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 590 INDIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 591 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 592 INDIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 593 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 594 MALAYSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 595 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 596 MALAYSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 597 MALAYSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 598 MALAYSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 599 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 600 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 601 MALAYSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 602 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 603 MALAYSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 604 MALAYSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 605 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 606 MALAYSIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 607 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 608 MALAYSIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 609 MALAYSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 610 MALAYSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 611 MALAYSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 612 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 613 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 614 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 615 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 616 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 617 MALAYSIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 618 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 619 MALAYSIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 620 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 621 SINGAPORE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 622 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 623 SINGAPORE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 624 SINGAPORE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 625 SINGAPORE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 626 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 627 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 628 SINGAPORE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 629 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 630 SINGAPORE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 631 SINGAPORE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 632 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 633 SINGAPORE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 634 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 635 SINGAPORE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 636 SINGAPORE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 637 SINGAPORE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 638 SINGAPORE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 639 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 640 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 641 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 642 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 643 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 644 SINGAPORE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 645 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 646 SINGAPORE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 647 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 648 PHILIPPINES MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 649 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 650 PHILIPPINES IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 651 PHILIPPINES CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 652 PHILIPPINES MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 653 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 654 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 655 PHILIPPINES CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 656 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 657 PHILIPPINES IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 658 PHILIPPINES CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 659 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 660 PHILIPPINES ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 661 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 662 PHILIPPINES IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 663 PHILIPPINES CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 664 PHILIPPINES PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 665 PHILIPPINES PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 666 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 667 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 668 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 669 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 670 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 671 PHILIPPINES HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 672 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 673 PHILIPPINES RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 674 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 675 INDONESIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 676 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 677 INDONESIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 678 INDONESIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 679 INDONESIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 680 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 681 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 682 INDONESIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 683 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 684 INDONESIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 685 INDONESIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 686 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 687 INDONESIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 688 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 689 INDONESIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 690 INDONESIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 691 INDONESIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 692 INDONESIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 693 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 694 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 695 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 696 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 697 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 698 INDONESIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 699 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 700 INDONESIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 701 REST OF ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 702 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 703 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 704 MIDDLE EAST AND AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 705 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 706 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 707 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 708 MIDDLE EAST AND AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 709 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 710 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 711 MIDDLE EAST AND AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 712 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 713 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 714 MIDDLE EAST AND AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 715 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 716 MIDDLE EAST AND AFRICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 717 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 718 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 719 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 720 MIDDLE EAST AND AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 721 MIDDLE EAST AND AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 722 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 723 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 724 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 725 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 726 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 727 MIDDLE EAST AND AFRICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 728 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 729 MIDDLE EAST AND AFRICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 730 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 731 SOUTH AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 732 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 733 SOUTH AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 734 SOUTH AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 735 SOUTH AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 736 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 737 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 738 SOUTH AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 739 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 740 SOUTH AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 741 SOUTH AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 742 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 743 SOUTH AFRICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 744 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 745 SOUTH AFRICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 746 SOUTH AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 747 SOUTH AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 748 SOUTH AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 749 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 750 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 751 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 752 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 753 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 754 SOUTH AFRICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 755 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 756 SOUTH AFRICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 757 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 758 SAUDI ARABIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 759 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 760 SAUDI ARABIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 761 SAUDI ARABIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 762 SAUDI ARABIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 763 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 764 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 765 SAUDI ARABIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 766 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 767 SAUDI ARABIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 768 SAUDI ARABIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 769 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 770 SAUDI ARABIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 771 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 772 SAUDI ARABIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 773 SAUDI ARABIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 774 SAUDI ARABIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 775 SAUDI ARABIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 776 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 777 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 778 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 779 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 780 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 781 SAUDI ARABIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 782 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 783 SAUDI ARABIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 784 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 785 U.A.E. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 786 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 787 U.A.E. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 788 U.A.E. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 789 U.A.E. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 790 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 791 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 792 U.A.E. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 793 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 794 U.A.E. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 795 U.A.E. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 796 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 797 U.A.E. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 798 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 799 U.A.E. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 800 U.A.E. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 801 U.A.E. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 802 U.A.E. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 803 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 804 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 805 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 806 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 807 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 808 U.A.E. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 809 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 810 U.A.E. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 811 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 812 KUWAIT MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 813 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 814 KUWAIT IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 815 KUWAIT CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 816 KUWAIT MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 817 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 818 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 819 KUWAIT CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 820 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 821 KUWAIT IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 822 KUWAIT CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 823 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 824 KUWAIT ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 825 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 826 KUWAIT IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 827 KUWAIT CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 828 KUWAIT PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 829 KUWAIT PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 830 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 831 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 832 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 833 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 834 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 835 KUWAIT HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 836 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 837 KUWAIT RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 838 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 839 BAHRAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 840 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 841 BAHRAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 842 BAHRAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 843 BAHRAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 844 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 845 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 846 BAHRAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 847 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 848 BAHRAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 849 BAHRAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 850 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 851 BAHRAIN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 852 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 853 BAHRAIN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 854 BAHRAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 855 BAHRAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 856 BAHRAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 857 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 858 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 859 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 860 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 861 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 862 BAHRAIN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 863 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 864 BAHRAIN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 865 REST OF MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 866 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 867 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 868 SOUTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 869 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 870 SOUTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 871 SOUTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 872 SOUTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 873 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 874 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 875 SOUTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 876 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 877 SOUTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 878 SOUTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 879 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 880 SOUTH AMERICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 881 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 882 SOUTH AMERICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 883 SOUTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 884 SOUTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 885 SOUTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 886 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 887 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 888 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 889 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 890 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 891 SOUTH AMERICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 892 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 893 SOUTH AMERICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 894 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 895 BRAZIL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 896 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 897 BRAZIL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 898 BRAZIL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 899 BRAZIL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 900 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 901 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 902 BRAZIL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 903 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 904 BRAZIL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 905 BRAZIL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 906 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 907 BRAZIL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 908 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 909 BRAZIL IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 910 BRAZIL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 911 BRAZIL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 912 BRAZIL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 913 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 914 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 915 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 916 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 917 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 918 BRAZIL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 919 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 920 BRAZIL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 921 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 922 ARGENTINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 923 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 924 ARGENTINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 925 ARGENTINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 926 ARGENTINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 927 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 928 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 929 ARGENTINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 930 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 931 ARGENTINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 932 ARGENTINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 933 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 934 ARGENTINA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 935 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 936 ARGENTINA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 937 ARGENTINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 938 ARGENTINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)

TABLE 939 ARGENTINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 940 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 941 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 942 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 943 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 944 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 945 ARGENTINA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 946 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 947 ARGENTINA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 948 REST OF SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)